| abstract |
Drug compositions for treatment of one or more inflammatory conditions can includes at least one of a theta-defensin, analog or derivative thereof. Inventive methods include researching theta- defensins, analogs or derivatives thereof for their efficacy with respect to anti-inflammatory effects, and providing such compositions to the market-place for the purpose of treating inflammatory conditions. Of particular interest are drug compositions effective to produce clinically relevant inhibition of tumor necrosis factor alpha (TNF-alpha)-converting enzyme (TACE) or other proinflammatory proteases, and/or sheddases, such as RTD-1-27, RTD-1-28 or RTD-1-29. It is contemplated that preferred compositions can be used to treat rheumatoid arthritis, inflammatory bowel disease, and other chronic inflammatory diseases, autoimmune diseases, cancer, and Alzheimer's, osteoarthritis, inflammation-related neurodegenerative and other inflammation-related diseases. |